Form 4: Kura Oncology CEO Vests 182,500 Shares

Kura Oncology's President and CEO, Troy Edward Wilson, acquired 182,500 shares of common stock through the vesting of performance-based restricted stock units after a development milestone was met.

Summary

• Troy Edward Wilson, President and CEO of Kura Oncology, Inc., acquired 182,500 shares of common stock.
• The acquisition occurred on November 13, 2025, at a price of $0 per share.
• These shares resulted from the vesting of performance-based restricted stock units (PSUs) that were granted on May 31, 2023.
• One of three specified development milestones was met on November 13, 2025, triggering this vesting event.
• This specific vesting event represents 1/6th of the total underlying shares from the PSU grant.
• Following this transaction, Wilson directly owns 429,353 shares of common stock.
• Indirect ownership includes 279,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust.

Sentiment

Score: 7

Explanation: The vesting of a significant number of shares for the CEO due to a milestone achievement is generally positive, indicating progress in the company's development objectives and aligning executive incentives with shareholder value. The $0 acquisition price reflects compensation rather than a market purchase.

Positives

• The vesting of 182,500 shares of common stock for the President and CEO indicates the successful achievement of a significant development milestone for Kura Oncology.
• The shares were acquired at a $0 cost, representing a direct increase in the executive's equity holdings and aligning management's interests with shareholder value.

Future Outlook

The remaining performance-based restricted stock units are contingent on the achievement of two additional specified development milestones and continuous service on corresponding vesting dates.

Industry Context

This filing is a standard disclosure of insider equity transactions and does not provide broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders may view the achievement of a development milestone and subsequent executive equity vesting as a positive indicator of company progress and management alignment.
• Employees may see this as a sign of the company meeting its strategic goals.

Next Steps

• Achievement of the remaining two specified development milestones for the full vesting of the performance-based restricted stock units.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Transaction, Stock Vesting, CEO, Restricted Stock Units, Performance-Based Compensation, Equity Compensation, Development Milestone